Lonza Posts Higher 2021 Sales; Confirms Mid-Term Targets

By Cecilia Butini

Lonza Group AG on Wednesday posted higher sales for full-year 2021 and reconfirmed its mid-term guidance until 2024.

The Swiss life-sciences company said core earnings before interest, taxes, depreciation and amortization grew to 1.67 billion Swiss francs ($1.82 billion), from CHF1.38 billion the year prior, on sales that grew to CHF5.41 billion from CHF4.51 billion.

Reported Ebitda fell to CHF1.37 billion from CHF1.38 billion because of a provision the company took for the environmental remediation of a landfill, it said.

Net profit also declined, coming in at CHF677 million, compared with CHF732 million in 2020, it said.

The company said it expects low- to mid-teens sales growth at constant exchange rates in 2022. It also reconfirmed its 2024 mid-term targets, saying that it expects a core Ebitda margin in line with the mid-term guidance already this year.

Write to Cecilia Butini at [e-mail]

(END) Dow Jones Newswires

01-26-22 0150ET